Anti-androgenic effect of *Symplocos racemosa* Roxb. against letrozole induced polycystic ovary using rat model

Mamata Jadhav¹, Sasikumar Menon², Sunita Shailajan³
¹Ramnarain Ruia College, Matunga, Mumbai 400019, India
²Institute for Advanced Training and Research in Interdisciplinary Science, 194, Scheme No. 6, Road No. 15, Sion Koliwada, Sion (E), Mumbai 400 022, India
³Herbal Research Lab, Ramnarain Ruia College, Matunga, Mumbai 400019, India

**Objective:** To investigate the anti-androgenic properties of *Symplocos racemosa* Roxb. (*S. racemosa*) in the treatment of hyperandrogenemia associated polycystic ovary syndrome (PCOS) in a letrozole induced PCOS rat model.

**Methods:** The testosterone levels were used to evaluate the anti-androgenic effect of *S. racemosa* in letrozole induced PCOS rats for 21 d. The low (250 mg/kg), mid (500 mg/kg) and high dose (1000 mg/kg) of *S. racemosa* was given to the PCOS induced rats for 15 d post letrozole induction to determine the effective dose of *S. racemosa* in the treatment of hyperandrogenemia associated PCOS. The hormones such as estrogen and progesterone were also assayed along with testosterone to determine the fluctuations in sex steroid levels in PCOS rats induced by letrozole.

**Results:** *S. racemosa* treatment significantly decreased testosterone levels which were found to be elevated in PCOS rats induced by letrozole. *S. racemosa* significantly restored other blood biochemical parameters such as estrogen, progesterone and cholesterol levels. It also restored the histology of ovarian tissue. The ovarian weights and uterine weights were also significantly recovered after the *S. racemosa* treatment.

**Conclusions:** The mid dose (500 mg/kg) and high dose (1000 mg/kg) of *S. racemosa* were found to be effective in the treatment of hyperandrogenemia in PCOS. This effect of *S. racemosa* was found to be comparable with clomiphene citrate. Clomiphene citrate which was being used as the major medicine in the treatment of PCOS could now be replaced with *S. racemosa* in the management of PCOS.

**Keywords**
*Symplocos racemosa* Roxb., Letrozole, Polycystic ovary syndrome, Clomiphene citrate

1. Introduction

Polycystic ovary syndrome (PCOS) is a heterogeneous disorder of unknown etiology affecting 5%–10% of women of reproductive age[1,2]. It is a disorder that affects the reproductive, endocrine and metabolic systems and it is the most common cause of anovulatory fertility[3,4]. Hyperinsulinemia and hyperandrogenemia are the chief culprits responsible for oligo/amenorrhoea, hirsutism, obesity and enlarged ovaries with small multiple cysts resulting in anovulation[5,6]. Although the etiology of PCOS is still not known, it is generally agreed that hyperandrogenemia is the heart of PCOS. The excess androgen levels are the root cause of PCOS producing the characteristic signs and symptoms which are then exacerbated by a propagation of excess ovarian androgen production from multiple small follicles, anovulation and insulin resistance in the reproductive life span, thus
setting up a vicious perpetual circle of androgen excess[7,8]. Thus androgen excess is the key element in PCOS and androgen levels are one of the most predictable markers of patients with PCOS[9]. While modern medicines such as hormonal therapies, anti-androgens, insulin sensitizers and clomiphene citrate address these concerns, often with undesirable adverse effects, the herbal medicines offer an option for women as a natural approach to reduce menstrual cycle discomforts[10]. Due to the lesser or no side effects, some of the herbal medicinal plants have been used for the treatment of various ailments related to different parts of the body and also disorders caused by hormonal imbalances related to the female reproductive system[11,12]. Herbal medicines have been recognized as a valuable and readily available resource for primary health care and WHO has endorsed their safe and effective use[13].

Symplocos racemosa Roxb. (S. racemosa) from the family Symplocaceae, is an evergreen tree or shrub found in the plains and lower hills throughout North and East India, ascending in the Himalayas up to an elevation of 1 400 m[14]. S. racemosa is a widely used Ayurvedic remedy mainly for gynecological disorders, It is also known as Lodhra and is used in Indian System of Medicine as single drug or in multicomponent preparations (viz. Lodhrasava). Traditionally bark is given in menorrhagia and other female reproductive dysfunctions which are some of the symptoms of PCOS[15]. The heterogeneity of PCOS is reflected by the existence of several animal models. Since the etiological factors are still unclear, it is challenging to create a single animal model that expresses all the PCOS characteristics[14]. Therefore the aim of this study was to investigate anti-androgenic properties of S. racemosa in the treatment of PCOS induced by chemical agent, letrozole in the rat model.

2. Materials and methods

2.1. Animals

Six–week–old female albino Wistar rats (mean body weight, 180 g) with 4 d regular estrus cycles were procured from Haffkine Biopharmaceuticals Limited, Parel, Mumbai. They are maintained at (25±2) °C and 45%–55% of humidity in 12 h light/12 h dark cycle. Animals were given free access to standard laboratory food (supplied by Amrut Feed) and water ad libitum[10,16]. Approval for carrying out the experiments was obtained from Institutional Animal Ethics Committee (CPCSEA/315).

2.2. Plant material of S. racemosa

The stem barks of S. racemosa were collected from their natural habitat from Mahabaleshwar, Maharashtra state of India. The plant species were taxonomically verified from Agharkar Research Institute, Pune. The voucher specimen number ARI 10–75 of 24/12/2010 was deposited in Herbal Research Laboratory of Ramnarin Ruia College, Matunga, Mumbai. The plant materials were washed thoroughly and dried at (37±5) °C before preparation of aqueous extract. The plant material was then powdered and stored in air tight bottles until use. The aqueous slurry of plant material was prepared in 2.0 mL of water before dosing.

2.3. Experimental design

The study was conducted on 42 female albino Wistar rats divided into seven groups of six rats each, including a control group that received vehicle only (1% aqueous solution of carboxymethyl cellulose once daily p.o. The six treatment groups rats were administered with letrozole (Femara® Manufactured by Novartis Pharma Stein AG, Stein, Switzerland) at concentrations of 1.0 mg/kg p.o. dissolved in 1% carboxymethyl cellulose (2.0 mL/kg) once daily. The treatment period was 21 d[16]. Along with normal control group, letrozole induced PCOS rats were divided into six treatment groups. The first PCOS group was left for natural recovery for 15 d post letrozole treatment. The second PCOS group was given repetitive dose of 1.0 mg/kg daily clomiphene citrate (Fertomid–50 Manufactured by Cipla Ltd., Kumrek, Rangpo Sikkim, 737132, India), a well known modern drug for the treatment of PCOS[10], one of the PCOS groups was sacrificed after 21 d of letrozole treatment. The other three PCOS groups were given repetitive doses of 250 mg/kg (low dose), 500 mg/kg (mid dose) and 1 000 mg/kg (high dose) of aqueous extract of S. racemosa once daily p.o. for 15 d post letrozole induction. Ovarian and uterine weight changes and hormonal assay were carried out in PCOS rats and the results were compared with that of the group treated with clomiphene citrate.

2.4. Blood sampling

At 24 h post the last dose of treatment and after 18 h fasting period, the rats were weighed and blood samples were collected by retino orbital puncture into different eppendorf tubes containing heparin sodium as an anticoagulant. The blood samples were centrifuged at 3000 r/min for 15 min and plasma was separated for hormonal assay. The plasma was stored in a freezer at –20 °C till further analysis.

2.5. Biochemical analysis

Plasma testosterone and estradiol were assayed by competitive chemiluminescent immunnoassay using automated instrument ADVIA Centaur, Bayer Diagnostics Europe Limited, Ireland. The testosterone was estimated using ADVIA Centaur TSTO kit and estrogen was estimated using ADVIA Centaur E2–6 kit[17]. The plasma progesterone was assayed by microparticle enzyme immunoassay using AXSYM analyzer–Abbott AXSYM® System, Abbott Japan[18]. The plasma cholesterol levels were assayed by using method of Wybenga and Rifelegi using Biolab Diagnostics Kit. The
plasma testosterone levels, estrogen levels, progesterone levels and cholesterol levels were recorded after letrozole induction of 21 d (i.e. on Day 22 of study period and after plant treatment for 15 d (i.e. on Day 37 of study period).

2.6. Tissue sampling

After blood sampling, the animals were sacrificed, ovaries and uterus were excised, cleaned off fat and weighed.

2.7. Histopathological examinations

The excised ovaries were fixed in Bouin’s fixative. Histopathological examinations of the ovaries were carried out using standardized histological methods. Sections of the ovary were cut from paraffin-embedded blocks. Histological examinations were carried out on hematoxylin–eosin stained sections using light microscopy.

2.8. Statistical analysis

Statistical analysis was performed using ANOVA followed by Dunnett’s test as a multiple comparison test. *P*<0.001, **P**<0.01, ***P***<0.05 and ****P****<0.01 were considered significant (19). Values were expresses as mean±SD.

3. Results

3.1. S. racemosa decreases testosterone levels

The plasma testosterone level in normal control group was observed to be around (235.82±14.98) ng/dL on Day 22 and is maintained consistently up to (245.33±13.84) ng/dL on Day 37 indicating the stable condition. After the animals were treated with letrozole for the induction of PCOS, the mean testosterone level in letrozole control group was significantly increased up to (795.20±24.10) ng/dL (*P*<0.001). Clomiphene citrate treatment led to a significant decrease in testosterone level from (716.37±28.86) ng/dL to (255.42±17.43) ng/dL. Significant fall of (279.95±21.30) ng/dL and (273.62±23.07) ng/dL (*P*<0.001) was recorded when PCOS induced rats were treated with mid and high dose of *S. racemosa* respectively. Decrease in testosterone level with low dose of *S. racemosa* was found to be (608.33±164.86) ng/dL (Table 1).

3.2. *S. racemosa* increases estrogen levels

Estrogen level increased significantly from (29.88±3.64) pg/mL to (48.00±5.48) pg/mL (*P*<0.001) in PCOS induced rats after clomiphene citrate treatment. Estrogen levels increased up to (43.83±3.19) pg/mL and (43.67±2.94) pg/mL (*P*<0.01) after repetitive administration of mid and high dose of *S. racemosa* respectively. No significant effect was recorded after the treatment with low dose of *S. racemosa* (Table 1).

3.3. *S. racemosa* increases progesterone levels

Progesterone level, which significantly decreased in PCOS rats from (8.81±0.81) ng/mL to (2.16±0.82) ng/mL (*P*<0.001) increased significantly to (7.02±0.77) ng/mL (*P*<0.001) due to clomiphene citrate treatment. *S. racemosa* treatment also elevated progesterone levels to (5.58±0.68) ng/mL with mid dose and (5.54±0.61) ng/mL with high dose (*P*<0.001). The decrease in progesterone level was found to be 4.63±0.37 (*P*<0.01) after the treatment with low dose of *S. racemosa* (Table 1).

3.4. *S. racemosa* decreases cholesterol levels

The cholesterol levels were found to be elevated significantly from (54.83±4.54) mg/dL to (92.83±9.54) mg/dL (*P*<0.001) in PCOS induced rats. A decrease in cholesterol levels to (49.00±4.65) mg/dL (*P*<0.01) was observed after clomiphene citrate treatment. A repetitive administration of mid and high dose of *S. racemosa* decreased cholesterol levels significantly to (72.83±4.88) mg/dL and (70.00±6.90) mg/dL (*P*<0.01) respectively. Low dose of *S. racemosa* did not show any significant effect in restoring cholesterol levels (Table 1).

3.5. *S. racemosa* decreases ovarian weights

There was a significant decrease in ovarian weight from (0.21±0.02) mg to (0.13±0.04) mg (*P*<0.01) after the treatment of PCOS induced rats with clomiphene citrate. When the PCOS induced rats were administered with low, mid and high dose of *S. racemosa*, the significant decrease to (0.16±0.01) mg and (0.15±0.01) mg (*P*<0.01) was recorded with mid and high dose of *S. racemosa* respectively. *S. racemosa* treatment with low dose did not show any significant effect on ovarian weights (Table 2).

### Table 1

| Groups                  | Testosterone (ng/mL) | Estrogen (pg/mL) | Progesterone (ng/mL) | Cholesterol (mg/dL) |
|-------------------------|----------------------|------------------|----------------------|--------------------|
|                         | 22nd day             | 37th day         | 22nd day             | 37th day           |                        |
| Normal control          | 235.82±14.98         | 245.33±13.84     | 55.83±5.19           | 8.81±0.81          | 58.00±7.43             | 54.83±4.54 |
| Letrozole control       | 29.88±3.64           | **2.16±0.82**    | **2.16±0.82**        | **2.16±0.82**      | **2.16±0.82**           |
| Natural recovery        | 795.20±24.10         | 759.73±55.39     | 34.67±4.03           | 31.17±7.94         | 3.42±0.07               | 3.42±0.07   |
| Clomiphene citrate      | 716.37±28.86         | 255.42±17.43     | **48.00±5.48**       | **7.02±0.77**      | **7.02±0.77**           |
| SR 250 mg/kg            | 759.73±55.39         | 785.47±27.40     | **56.17±3.66**       | **96.00±5.54**     | **96.00±5.54**          |
| SR 500 mg/kg            | 279.95±21.30         | **273.62±23.07** | **279.95±21.30**     | **49.00±8.65**     | **49.00±8.65**          |
| SR 1 000 mg/kg          | 30.00±3.69           | **30.00±3.69**   | **30.00±3.69**       | **72.83±4.88**     | **72.83±4.88**          |

**SR: S. racemosa; NS:** not significant compared with normal control group; **P:** <0.001; ***P*:** <0.01; ****P****:** <0.05; compared with normal control group; **:** P<0.05; ***:** P<0.01; ****:** P<0.001 compared with modern drug group.
3.6. *S. racemosa* increases uterine weights

The uterine weights which decreased from (1.71±0.28) mg to (0.57±0.09) mg (*P*<0.001) in PCOS induced rats, increased significantly to (1.15±0.28) mg (*P*<0.001) after clomiphene citrate treatment. The repetitive administration of mid and high dose of *S. racemosa* also led to a significant increase in uterine weights to (1.69±0.24) mg and (1.58±0.21) mg (*P*<0.001) respectively (Table 2).

**Table 2**

| Groups                  | Ovarian weights | Uterine weights |
|-------------------------|-----------------|-----------------|
| Normal control          | 0.14±0.03       | 1.71±0.28       |
| Letrozole control       | 0.21±0.02       | 0.75±0.09       |
| Natural recovery        | 0.20±0.02       | 0.70±0.15       |
| Clomiphene citrate      | 0.13±0.04       | 1.15±0.28       |
| SR 250 mg/kg            | 0.19±0.03       | 0.78±0.37       |
| SR 500 mg/kg            | 0.16±0.01       | 1.09±0.24       |
| SR 1000 mg/kg           | 0.15±0.05       | 1.28±0.21       |

SR: *S. racemosa*; NS: *P*>0.01; a*: *P*<0.05; a**: *P*<0.01; a***: *P*<0.001 compared with letrozole control group; b*: *P*>0.01; b**: *P*<0.05; b***: *P*<0.001 compared with normal control group; c*: *P*>0.01; c**: *P*<0.05; c***: *P*<0.001 compared with modern drug group.

3.7. *S. racemosa* improves ovarian histology in PCOS rats

The significant number of atretic follicles were found in the cortex of ovary from letrozole induced PCOS rats. Atretic secondary follicles were randomly interspread among normal follicles. In addition to marked atresia, description of the granulosa layer was also seen. Many cysts were found. Theca layer was found to be delineating, dying cells and the debris was collected in the antrum (Figure 1C and Figure 2A). When rats with PCOS were left for natural recovery, the recovery was not to its potential as compared to plant and clomiphene citrate treatment as many cysts and atretic follicles were still found (Figure 2B). *S. racemosa* treatment with mid and high dose resulted in the ovarian tissue to show marked recovery of follicle with intact structure of granulosa layer and thecal layer. The ovary showed presence of well developed antral follicle with oocyte and antrum which appeared to be clear without any cell debris (Figure 2C and Figure 3).

**Figure 1.** Ovarian histology in rats.  
a: Section of ovary from normal rat showing the presence of antral follicles (F) and corpus luteum (CL) (H&E, ×4). b: Section of ovary from normal rat showing the presence of antral follicle (F) with antral cavity (A), oocyte (O) surrounded by granulosa cells (G), corona radiata (CR), cumulus oophorus (CO) and thecal layer (TL) (H&E, ×10). c: Section of ovary from PCOS rat exhibiting many cystic degenerating follicles (C) with thin granulosa layer (H&E, ×4).

**Figure 2.** Ovarian histology in PCOS rats.  
a: Section of ovary from PCOS rat with cystic degenerating follicle (C) with thin granulosa layer and atretic follicle (AF) with degenerated granulosa layer (G), delineated thecal layer (TL) and the antrum (A) filled with the cell debris and dying cells (H&E, ×10). b: Section of ovary from PCOS rat left for natural recovery exhibiting atretic follicle (AF) with degenerating granulosa layer (G) and delineated thecal layer (TL) (H&E, ×10). c: Section of ovary from PCOS rat treated with clomiphene citrate showing marked recovery with the presence of antral follicle (F) with intact thecal layer (TL), granulosa layer (G) and oocyte (O) with corona radiata (CR) and cumulus oophorus (CO) (H&E, ×10).

**Figure 3.** Ovarian histology in PCOS rats treated with *S. racemosa*.  
a: Section of ovary from PCOS rat treated with *S. racemosa* 500 mg/kg showing the presence of developing follicles (F) and corpus luteum (CL) in the ovarian cortex (H&E, ×4). b: Section of ovary from PCOS rat treated with *S. racemosa* 500 mg/kg showing the presence of normal antral follicle (F) with clear antrum (A), and oocyte (O) surrounded by cumulus oophorus (CO), granulosa layer (G) and thecal layer (TL) (H&E, ×10). c: Section of ovary from PCOS rat treated with *S. racemosa* 1000 mg/kg showing the presence of normal developing follicle (F) with oocyte (O) (H&E, ×10).

4. Discussion

Polycystic ovaries may be created *de novo* as a result of exogenous androgen administration or secondarily to endogenous androgen excess[20]. Abnormal follicular maturation or acceleration of follicular atresia was reported in presence of elevated intraovarian androgen levels. Therefore, intraovarian androgen excess resulting from either circulating hyperandrogenemia or abnormal steroidogenesis may result in abnormal follicular development and polycystic ovary. Testosterone and androstenedione were converted into estradiol and estrone, respectively, by P450 aromatase, which was expressed in ovary. A decrease in activity of this enzyme could be expected to result in increased ovarian androgen production and development of PCOS[16]. In the present study, the animal model with PCOS was developed...
using non-steroidal aromatase inhibitor letrozole in rat which showed many histologic and biochemical findings consistent with human PCOS. In polycystic ovary syndrome, the testosterone levels increase in humans[12,16,21–23]. The similar results were obtained in the present research work. In the present research work, when the rats were induced with PCOS by letrozole, the testosterone levels were found to be significantly increased when compared with normal rats. PCOS induced rats treated with S. racemosa showed reduced levels of testosterone.

Earlier findings, have reported that being a non-steroidal aromatase inhibitor letrozole blocks the conversion of testosterone to estradiol. This leads to the reduction in estrogen production[12,16,24–26]. The similar effect was seen in the present research work. The PCOS induced rats showed decreased levels of estrogen. Repetitive administration of S. racemosa led to a significant increase in estrogen levels. The plasma progesterone levels decreased significantly after induction of PCOS with Letrozole. This is in accordance with the earlier observations[12,16,22,24]. Increased progesterone levels were observed when the PCOS induced rats were repetitively administered with mid and high dose of S. racemosa.

Women with PCOS are hyperandrogenemic which is associated with alterations in circulating lipids and lipoprotein levels resulting in dyslipidemia. Characteristically PCOS patients have elevated cholesterol levels[23,27]. The patients with PCOS tend to be obese, probably due to high lipid and cholesterol content. The similar effect was seen in the current research work after the induction of PCOS. The PCOS induced rats showed elevated cholesterol levels which decreased significantly when the PCOS induced rats were treated with S. racemosa.

Ovarian weight in PCOS induced rats was more than the normal rats which is in accordance with the earlier findings[12,16,23–26]. The treatment with S. racemosa prevented further increase in ovarian weight. In the present research work, the uterine weight was found to be decreased in PCOS induced rats. This coincides with the earlier findings[16]. The uterine weights were returned to the normalcy when the treatment of S. racemosa was given to the PCOS induced rats.

The biochemical results are also supported by histopathological observations of light microscopy. It is reported that the histopathological study of PCOS induced rats show the formation of cysts in the ovary[16,22,24]. The ovarian cortex shows the presence of atretic follicles and the formation of more than two cysts in the ovary. The cysts show the attenuated layer of granulosa cells and hyperplasia of theca lutein[16,24,28]. Atretic follicles exhibit massive degeneration and sloughing-off of the central granulosa layer into the antrum. Thus the follicles become atretic with the presence of dying cells and debris in the antrum. In PCOS condition the corpora lutea do not form or the number of corpora lutea are diminished indicating anovulation and the frequency of estrus cycle is almost nil in PCOS rats[10,24,28]. In PCOS high local androgen concentrations are responsible for anovulation by direct effect on the ovary. Androgen-induced follicular atresia is thought to occur by entry of androgens into the granulosa layer of pre-antral follicles, where they bind to the cell receptors and cause the cell death. Androgens cause deterioration of follicles by increasing the number of pycnotic granulosa cells and degenerating oocytes[29]. The similar observations were seen in the current research work when the rats were induced with PCOS by Letrozole. The histopathological observations of the S. racemosa treated group showed marked recovery of the ovarian tissue with the presence of normalized structure of antral follicle. The light microscopic observations also revealed the presence of many well defined antral follicles in the process of normalizing. The follicles showed normal granulosa and defined theca layers. The follicles also showed the presence of a clear antrum free of any cell debris. The presence of corpora lutea was also seen after plant treatment suggesting that treatment with S. racemosa restored estrous cyclicity back to normal. The ovarian cortex showed the presence of many follicles in the various stages of development.

The effect of S. racemosa treatment with mid and high dose was found to be comparable with that of clomiphene citrate alone while no significant changes were observed with low dose of S. racemosa treatment in the normalization of various parameters in the PCOS induced rats.

S. racemosa treatment exhibited significant recovery of testosterone, estrogen, progesterone levels and ovarian tissues. S. racemosa showed good anti-androgen effect by reducing increased androgen levels and prevented ovarian cell dysfunction in PCOS to improve fertility. The observed recovery of ovarian tissue as well as anti-androgen potential of S. racemosa may be responsible for its efficacy in the management of PCOS. This might be helpful to understand the role of S. racemosa in the management of PCOS. Findings of the current study can provide a baseline data for designing further investigations on the therapeutic benefits of S. racemosa as an adjunct therapy along with modern drug in the management of PCOS so as to reduce the side effects of modern drug without compromising the therapeutic activity.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgements

All the authors are thankful to the financial support provided by Therapeutic Drug Monitoring Laboratory, Mumbai 400 022, India and the Grant No. is CL/TDMI/SM/10–11/452A.

Comments

Background

S. racemosa Roxb. commonly known as Lodhra is widely used as a traditional medicine in the treatment of gynecological disorders. Due to the undesirable adverse effects of modern medicines, herbal medicines can be used to treat disorders caused by hormonal imbalances related to the female reproductive system. Since the increased androgen levels are characteristic clinical features of PCOS, the antiandrogenic properties of S. racemosa Roxb. were evaluated in the treatment of PCOS using in vivo animal model.
Research fronts

The study was performed by using letrozole induced PCOS rat model to determine the effective dose of S. racemosa Roxb. in the treatment of PCOS.

Related Reports

No work has been reported on the use of S. racemosa Roxb. as a herbal remedy in the treatment of PCOS and the findings of the study were in accordance with the earlier findings reported for the other plants.

Innovations and breakthroughs

S. racemosa Roxb. possesses anti–androgenic properties in the treatment of hyperandrogenism associated with PCOS.

Applications

Due to the potential anti–androgen effect of S. racemosa Roxb., the modern drug therapy for PCOS can now be replaced with S. racemosa Roxb. as an alternative therapy so as to reduces the side effects of modern drug.

Peer review

This study contributes to the understanding of effect of S. racemosa Roxb. on upon the reproductive tract of females. The hypothesis of the authors was ascertained and the results provided the good evidence to support its use in the reproductive medicine in the treatment of PCOS.

References

[1] Dasgupta S, Reddy BM. Present status on understanding on the genetic etiology of polycystic ovary syndrome. J Postgrad Med 2008; 54(2): 114–125.

[2] Goswami PK, Khale A, Ogale S. Natural remedies for polycystic ovarian syndrome (PCOS); a review. Int J Pharm Phytopharm Res 2012; 1(6): 396–402.

[3] Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in women with polycystic ovary syndrome (PCOS). Eur J Endocrinol 2008; 159: 456–488.

[4] Amer SAK. Polycystic ovarian syndrome: diagnosis and management. J Obstet Gynecol India 2005; 55(1): 67–71.

[5] Ravevalle C, Salvetti NR, Mira GA, Pezzone N, Ortega HH. Microscopic characterization of follicular structures in letrozole–induced polycystic ovarian syndrome in the rat. J Med Food 2009; 12(9): 1270–1278.

[6] Siriwattsan S, Kanathilaka LPA, Kodituwakku ND, Karunarathne YAUD. Clinical efficacy of Ayurveda treatment regimen on subfertility with polycystic ovarian syndrome (PCOS). Ayu 2010; 31(1): 24–27.

[7] Azziz R, Carmina E, Dewailly D, Kandarakis ED, Escobar–Morreale HF, Futterweit W, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete force report. Fertil Steril 2009; 91(2): 456–488.

[8] Sharma HK, Sharma RK. Evaluation of efficacy and safety of Evkeley® syrup in infertility due to polycystic ovary syndrome. Indian J Clin Pract 2010; 21(2): 127–132.

[9] Grant P. Spearmint herbal tea has significant anti–androgen effect in polycystic ovary syndrome: a randomized controlled trial. Phytother Res 2010; 24: 186–188.

[10] Sasikala SL, Shamila S. A novel ayurvedic medicine–Ashokarishtam in the treatment of letrozole induced PCOS in rat. J Cell Tissue Res 2009; 9(2): 1903–1907.

[11] Chen JT, Tominaga K, Sato Y, Anzai H, Matsuoka R. Maitake mushroom (Grifola frondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first–line clomiphene citrate. J Altern Complement Med 2010; 16(2): 1295–1299.

Mishra D, Sinha M. Ayurvedic management of polycystic ovary syndrome. J Res Edu Indi Med 2008; 14: 33–40.

Lavekar GS, Padhi MM, Mangal AK, Joseph GVR, Raman KG, Selvarajan S, et al. Database on medicinal plants used in Ayurveda. New Delhi: Central Council for Research in Ayurveda & Siddha; 2008.

Bhutani KK, Jadav AN, Kalia V. Effect of Sycnodos racemosa Roxb. on gonadotropin release in immature female rats and ovarian histology. J Ethnopharmacol 2004; 94: 197–200.

Kafali H, Iriadiam M, Ozardali, Demir N. Letrozole induced polycystic ovaries in the rat: a new rat model for cystic ovarian disease. Arch Med Res 2004; 35: 103–108.

Bhandopadhyay SK, Chakrabarti R, Banerjee S, Pathak SK, Chakravarty RN, et al. Galactose toxicity in the rat as a model for premature ovarian failure: an experimental approach readressed. Hum Reprod 2003; 18(10): 2031–2038.

Bhattacharya D, Mandal SK, Mukherjee S, Pradhan M. Clinical correlation with biochemical status in polycystic ovarian syndrome. J Obstet Gynecol India 2005; 55(1): 67–71.

Baravalle C, Salvetti NR, Mira GA, Pezzone N, Ortega HH. Microscopic characterization of follicular structures in letrozole–induced polycystic ovarian syndrome in the rat. J Med Food 2009; 12(6): 830–839.

Desai BN, Marhaj RN, Nampoothiri LP. Aloe barbadensis Mill. formulation restores lipid profile to normal in a letrozole–induced polycystic ovarian syndrome rat model. Pharmacognosy Res 2012; 4: 109–115.

Rezvanfar MA, Rezvanfar MA, Ahmadi A, Shojai–Saadi HA, Baerei M, Abdollahi M. Molecular mechanism of a novel selenium based complementary medicine which confers protection against hyperandrogenism induced polycystic ovary. Theriogenology 2012; 78: 620–631.

Maharjan R, Nagar PS, Nampoothiri L. Effect of Aloe barbadensis Mill. formulation on letrozole induced polycystic ovarian syndrome rat model. J Ayurved Integr Med 2010; 1(4): 273–279.

Manneras L, Cajander S, Holmang A, Selvikovic Z, Lystig T, Lonn M, et al. A new rat model exhibiting both ovaria and metabolic characteristics of polycystic ovarian syndrome. Endocrinology 2007; 148: 3781–3791.

Sasikala SL, Shamila S. Unique rat model exhibiting biochemical fluctuations of letrozole induced polycystic ovary syndrome and subsequent treatment with allopathic and ayurvedic medicines. J Cell Tissue Res 2009; 9(2): 203–2017.

Brawer JR, Munoz M, Farookhi, R. Development of the polycystic ovarian condition (PCO) in the estradiol valerate–treated rat. Biol Reprod 1986; 35: 647–655.

De leo Y, Lanzetta D, D’antona D, La Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83(1): 99–102.